The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
염증 표지자를 기반으로 한 COVID-19에서의 코르티코스테로이드 또는 토실리주맙의 사용
Article
[키워드] administer
Admission
C-reactive protein
cause of death
collected
Combination
Corticosteroids
COVID-19
COVID-19 patients
CRP
D-dimer values
death in COVID-19
Efficacy
Escalation
evaluate
ferritin
HFNC
high risk
High-flow nasal cannula
Hospital mortality
ICU
IMV
in-hospital mortality
inclusion criteria
Inflammation
inflammatory cascade
intensive care
intensive care unit
Invasive mechanical ventilation
Lactate
lactate dehydrogenase
LDH
lower mortality
lymphocyte
Lymphocyte count
mechanical ventilation
Mortality
nasal
nasal cannula
NIMV
no significant differences
Non-invasive
non-invasive mechanical ventilation
outcome
Patient
patients
prescription
Primary outcome
propensity score matching
registry
retrospective cohort study
Risk category
secondary
Secondary outcomes
significant difference
Spanish
statistically significant
TCZ
therapy
Tocilizumab
treat
treated
Treatment
[DOI] 10.1007/s11606-021-07146-0 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s11606-021-07146-0 PMC 바로가기 [Article Type] Article